Krishna Institute of Medical Sciences has received in-principle approvals from both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) for a preferential allotment of warrants to its promoter group. The company will issue 77,02,182 warrants, fully convertible into equity shares with a face value of ₹2 each, priced at not less than ₹779 per share. This capital raise strengthens the promoter stake through Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP, subject to final allotment and listing formalities.

The regulatory approvals were granted under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had submitted its application on June 17, 2026. Both exchanges have mandated strict compliance with internal controls to monitor trades executed by the proposed allottees before the allotment date. This is intended to prevent non-compliances regarding intra-day trading or sales in the company’s scrip prior to the security allotment, as required under Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The company is advised to obtain undertakings from the allottees confirming they will not engage in intra-day trading or sell the scrip until the allotment date. The issuer bears sole responsibility for verifying these undertakings and ensuring compliance with Regulation 167(6) of the SEBI ICDR regulations. Any observed non-compliance post-verification may impact the listing of the shares.

Listing and Compliance Requirements

Following the allotment, Krishna Institute of Medical Sciences must file a listing application without delay, along with applicable fees, in terms of Regulation 14 of the LODR Regulations. As per Schedule XIX – Para (2) of the ICDR Regulations and SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, the company must apply for listing within twenty days from the date of allotment. Failure to comply attracts fines as specified in the same circular.

The exchanges reserved the right to withdraw the in-principle approval if submitted information is found incomplete, incorrect, misleading, or false, or if it contravenes any rules, bye-laws, or regulations. The company must also secure all necessary statutory and other approvals from authorities including SEBI, RBI, and MCA before proceeding.

What the Numbers Show

The pricing of the warrants at not less than ₹779 per share establishes a clear valuation floor for this preferential issue. By structuring the issuance as fully convertible warrants rather than immediate equity, the promoters gain flexibility in timing the conversion while adhering to lock-in and trading restrictions imposed by the exchanges. The requirement for enhanced internal controls highlights the regulatory focus on preventing market abuse during the pre-allotment period.

Krishna Institute of Medical Sciences Limited will convene its 24th Annual General Meeting (AGM) on Thursday, August 27, 2026, at 4:00 PM IST via Video Conferencing/Other Audio Visual Means (VC/OAVM). The meeting aims to adopt the audited financial statements for FY26, re-appoint a retiring director, and seek shareholder approval for significant financial powers, including loan and guarantee limits up to ₹650 crore. This approval is critical for the company’s ongoing capital expenditure and working capital requirements within the KIMS group.

The notice, issued pursuant to Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was published in Financial Express and Navatelangana on August 6, 2026. The filing outlines both ordinary and special business items, ensuring compliance with corporate governance norms while facilitating remote participation for shareholders.

Key Resolutions for Approval

The AGM agenda features three critical resolutions requiring shareholder consent:

Under Item 3, the Board seeks to ratify the remuneration of ₹6.00 Lakhs, excluding applicable taxes, payable to M/s. Sagar & Associates for conducting the cost audit for FY27. This appointment was recommended by the Audit Committee.

Financial Powers and Compliance

Items 4 and 5 involve special resolutions to expand the company’s financial flexibility. Under Section 185 of the Companies Act, 2013, the Board seeks approval to provide loans, guarantees, or securities to subsidiaries, associates, or joint ventures where directors have an interest, up to ₹650 crore over and above Section 186 limits. Similarly, under Section 186, the Board seeks approval for loans, guarantees, or investments in other bodies corporate up to ₹650 crore over the statutory limit of 60% of paid-up capital, free reserves, and securities premium, or 100% of free reserves and securities premium, whichever is higher.

The explanatory statement clarifies that these funds are intended for principal business activities, working capital requirements, and capital expenditure for new projects within the KIMS group. The Audit Committee will monitor these transactions periodically to ensure compliance with arm’s length principles and regulatory requirements. No directors or key managerial personnel have a financial interest in these resolutions.

Voting and Participation Details

Shareholders holding shares as of the record date, August 20, 2026, are eligible to vote. Remote e-voting will be available from August 24, 2026, at 9:00 AM IST to August 26, 2026, at 5:00 PM IST, facilitated by MUFG Intime India Private Limited. Members who vote remotely may still attend the AGM via VC/OAVM but cannot vote again during the meeting. Physical attendance is dispensed with as per Ministry of Corporate Affairs circulars.